Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine.

Gruden MA, Davidova TV, Yanamandra K, Kucheryanu VG, Morozova-Roche LA, Sherstnev VV, Sewell RD.

Behav Brain Res. 2013 Apr 15;243:205-12. doi: 10.1016/j.bbr.2013.01.011. Epub 2013 Jan 17.

PMID:
23333843
2.

Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.

Gruden MA, Davydova TV, Narkevich VB, Fomina VG, Wang C, Kudrin VS, Morozova-Roche LA, Sewell RD.

Behav Brain Res. 2014 Apr 15;263:158-68. doi: 10.1016/j.bbr.2014.01.017. Epub 2014 Jan 27.

PMID:
24480422
3.

Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms.

Gruden MA, Davydova TV, Narkevich VB, Fomina VG, Wang C, Kudrin VS, Morozova-Roche LA, Sewell RD.

Behav Brain Res. 2015 Feb 15;279:191-201. doi: 10.1016/j.bbr.2014.11.001. Epub 2014 Nov 18.

PMID:
25446742
4.

Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.

Decressac M, Mattsson B, Björklund A.

Exp Neurol. 2012 May;235(1):306-15. doi: 10.1016/j.expneurol.2012.02.012. Epub 2012 Feb 25.

PMID:
22394547
5.

Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ.

Exp Neurol. 2002 May;175(1):35-48.

PMID:
12009758
6.

alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.

Bazzu G, Calia G, Puggioni G, Spissu Y, Rocchitta G, Debetto P, Grigoletto J, Zusso M, Migheli R, Serra PA, Desole MS, Miele E.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. Review.

PMID:
20522009
7.

Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation.

Gruden MA, Yanamandra K, Kucheryanu VG, Bocharova OR, Sherstnev VV, Morozova-Roche LA, Sewell RD.

Neuroimmunomodulation. 2012;19(6):334-42. doi: 10.1159/000341400. Epub 2012 Sep 11.

8.

Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.

Wakamatsu M, Iwata S, Funakoshi T, Yoshimoto M.

J Neurosci Res. 2008 Feb 15;86(3):640-6.

PMID:
17896793
9.

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.

Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.

Neuroscience. 2011 Apr 28;180:280-92. doi: 10.1016/j.neuroscience.2011.02.017. Epub 2011 Feb 16.

PMID:
21333719
10.

Generation of a alpha-synuclein-based rat model of Parkinson's disease.

Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.

Neurobiol Dis. 2008 Apr;30(1):8-18. doi: 10.1016/j.nbd.2007.11.002. Epub 2007 Nov 13.

PMID:
18313315
11.

Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.

Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai R.

J Mol Biol. 2009 Apr 3;387(3):771-85. doi: 10.1016/j.jmb.2009.02.007. Epub 2009 Feb 11.

PMID:
19361420
12.

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A.

Neuron. 2000 Jan;25(1):239-52.

13.

Different species of alpha-synuclein oligomers induce calcium influx and seeding.

Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M.

J Neurosci. 2007 Aug 22;27(34):9220-32.

14.

Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.

Rojo AI, Montero C, Salazar M, Close RM, Fernández-Ruiz J, Sánchez-González MA, de Sagarra MR, Jackson-Lewis V, Cavada C, Cuadrado A.

Eur J Neurosci. 2006 Oct;24(7):1874-84.

PMID:
17067291
15.

The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.

Wan OW, Chung KK.

PLoS One. 2012;7(6):e38545. doi: 10.1371/journal.pone.0038545. Epub 2012 Jun 12.

16.

Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.

Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF.

FASEB J. 2005 Aug;19(10):1377-9. Epub 2005 Jun 9.

PMID:
15946991
17.

The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding.

Pham CL, Cappai R.

Biosci Rep. 2013 Oct 22;33(5). pii: e00074. doi: 10.1042/BSR20130092.

18.

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.

19.

Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A.

Exp Neurol. 2008 Mar;210(1):182-93. Epub 2007 Nov 1.

PMID:
18053987
20.

Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease.

Xie W, Chung KK.

J Neurochem. 2012 Jul;122(2):404-14. doi: 10.1111/j.1471-4159.2012.07769.x. Epub 2012 May 23.

Supplemental Content

Support Center